PUBLISHER: Grand View Research | PRODUCT CODE: 2018195
PUBLISHER: Grand View Research | PRODUCT CODE: 2018195
The global continuous glucose monitoring devices market size was valued at USD 13.38 billion in 2025 and is projected to reach USD 49.87 billion by 2033, growing at a CAGR of 15.10% from 2026 to 2033. This growth is attributed to clinical needs, technological innovation, and shifting care models.
Another primary factor for market growth is the rising global prevalence of diabetes, which has intensified the demand for more efficient and real-time glucose monitoring solutions. Traditional blood glucose testing is often invasive, intermittent, and inconvenient, prompting both patients and providers to adopt continuous glucose monitoring (CGM) systems for better glycemic control and improved quality of life. According to the International Diabetes Federation (IDF), as of 2024, there are approximately 589 million adults living with diabetes worldwide.
CGM devices are minimally invasive and offer an easy and effective way to manage diabetes. They can also detect drastic changes in blood glucose levels, thereby preventing hypoglycemic conditions. The continuous glucose monitoring (CGM) devices facilitate the analysis of blood glucose levels at different time intervals with the help of a sensor. Respective readings fed into diabetes management software through a wireless network allow patients to understand the disease better, thereby helping them to manage it more effectively. Smoking, obesity, physical inactivity, high blood pressure, and high cholesterol are the common risk factors associated with diabetes complications. For instance, in January 2024, Medtronic received CE Mark approval in Europe for its MiniMed 780G system with Simplera Sync, a next-generation, minimally invasive CGM sensor that integrates fully with its automated insulin delivery pump.
The market is also witnessing a shift toward the increasing demand for personalized, real-time diabetes care. Unlike traditional fingerstick glucose monitoring, CGM devices offer continuous insights into glucose trends, helping patients and healthcare providers make proactive decisions. For instance, in August 2024, Abbott and Medtronic announced a global partnership to integrate Abbott's FreeStyle Libre CGM technology with Medtronic's automated insulin delivery systems. This was a critical step towards simplifying diabetes management and reducing the burden of constant self-monitoring. According to a key personnel member at Abbott Laboratories' Diabetes Care Division,
Global Continuous Glucose Monitoring Devices Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the study, Grand View Research has segmented the continuous glucose monitoring devices market report based on product, connectivity, indication, distribution channel, and region: